Quadrant Capital Group LLC Karuna Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$161.01 - $317.85 $8,050 - $15,892	50 Added 94.34%	103 $32,000
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $1,811 - $2,398	11 Added 26.19%	53 $8,000
Q2 2023 Aug 09, 2023	BUY	$176.32 - $240.22 $176 - $240	1 Added 2.44%	42 $9,000
Q1 2023 May 11, 2023	SELL	$161.33 - $204.36 $7,582 - $9,604	-47 Reduced 53.41%	41 $7,000
Q4 2022 Feb 10, 2023	BUY	$191.53 - $236.82 $2,681 - $3,315	14 Added 18.92%	88 $17,000
Q3 2022 Nov 10, 2022	BUY	$123.79 - $277.42 $4,085 - $9,154	33 Added 80.49%	74 $17,000
Q2 2022 Aug 09, 2022	BUY	$93.97 - $143.33 $3,852 - $5,876	41 New	41 $5,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.